Trek Therapeutics, with CMO and co-founder Robert Hindes, MD, has a mission of expanding access to effective treatments for hepatitis C by means of development of affordable drugs. Hepatitis-C currently infects about 200 million people worldwide. HCV is chronic in the great majority of individuals infected with the virus, and can result in death through severe liver damage and/or liver cancer. It is the mission of Trek Therapeutics and Robert Hindes, MD, to substantially increase the number of patients treated for HCV through public health initiatives and expanded access.

2.  Trek Therapeutics, with CMO and co-founder
Robert Hindes, MD, has a mission of expanding
access to effective treatments for hepatitis C
by means of development of affordable drugs.
Hepatitis-C currently infects about 200 million
people worldwide. HCV is chronic in the great
majority of individuals infected with the virus,
and can result in death through severe liver
damage and/or liver cancer. It is the mission of
Trek Therapeutics and Robert Hindes, MD, to
substantially increase the number of patients
treated for HCV through public health
initiatives and expanded access.

3.  HCV is most often transmitted through
exposure to infected blood. It is most
commonly spread through the use of shared
needles, syringes, razors, toothbrushes, nail
clippers, and body piercing and tattooing
equipment, and can also be spread through
blood transfusions that have not been
screened for the disease. The risk of
transmission through sexual contact is very low,
but this risk increases with the number of sexual
partners. In approximately 2% of cases, the
Hepatitis-C infection is passed from a mother to
her baby.

4.  The number of individuals infected with
HCV is greater than the number infected
with AIDS. Due to the lack of education
about preventive measures and safety,
the disease has an increasing
prevalence in some lesser-developed
countries. To find out more about Trek
Therapeutics' quest for a low-cost drug,
visit www.trektx.com.